Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

S&P Biotech SPDR (XBI)

S&P Biotech SPDR (XBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Price/Earnings ttm 17.88
  • Annual Dividend & Yield 0.13 (0.15%)
  • Most Recent Dividend 0.003 on 12/23/24
  • Management Fee 0.35%
  • INDUSTRY GROUPING:

    ETFs - Biotech

Options Overview Details

View History
  • Implied Volatility 29.17% ( -1.31%)
  • Historical Volatility 22.50%
  • IV Percentile 68%
  • IV Rank 40.72%
  • IV High 38.19% on 08/05/24
  • IV Low 22.98% on 11/12/24
  • Put/Call Vol Ratio 1.66
  • Today's Volume 43,814
  • Volume Avg (30-Day) 40,652
  • Put/Call OI Ratio 1.51
  • Today's Open Interest 588,375
  • Open Int (30-Day) 586,737

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.07 +5.02%
on 03/04/25
93.86 -5.93%
on 02/21/25
-3.12 (-3.41%)
since 02/14/25
3-Month
84.07 +5.02%
on 03/04/25
94.90 -6.97%
on 02/05/25
-6.30 (-6.66%)
since 12/17/24
52-Week
81.14 +8.81%
on 04/25/24
105.47 -16.29%
on 11/11/24
-6.42 (-6.78%)
since 03/15/24

Most Recent Stories

More News
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

SGMO : 1.0100 (+2.94%)
VTI : 279.28 (+0.83%)
XBI : 88.29 (+1.33%)
SCHA : 24.05 (+1.31%)
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

VTI : 279.28 (+0.83%)
XBI : 88.29 (+1.33%)
IWM : 205.45 (+1.26%)
SWTX : 49.84 (-2.54%)
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy

The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy.

VTI : 279.28 (+0.83%)
XBI : 88.29 (+1.33%)
IWM : 205.45 (+1.26%)
CAPR : 12.88 (-2.65%)
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

EBS : 5.79 (+1.40%)
AVUV : 87.93 (+1.05%)
VTI : 279.28 (+0.83%)
XBI : 88.29 (+1.33%)
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week

Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.

TGTX : 41.06 (+0.54%)
IJR : 106.12 (+1.07%)
VTI : 279.28 (+0.83%)
XBI : 88.29 (+1.33%)
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook

CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.

IJR : 106.12 (+1.07%)
ADMA : 18.67 (+1.30%)
VTI : 279.28 (+0.83%)
XBI : 88.29 (+1.33%)
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print

The company plans to unveil details at its virtual R&D Day on March 13.

ALT : 5.97 (+0.84%)
VTI : 279.28 (+0.83%)
IWM : 205.45 (+1.26%)
XBI : 88.29 (+1.33%)
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’

The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and investments....

VXF : 177.57 (+1.44%)
MNKD : 5.24 (+0.77%)
XBI : 88.29 (+1.33%)
IWM : 205.45 (+1.26%)
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

ARQT : 16.42 (+12.31%)
VTI : 279.28 (+0.83%)
IWM : 205.45 (+1.26%)
XBI : 88.29 (+1.33%)
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

VTI : 279.28 (+0.83%)
ARDX : 5.42 (-0.91%)
IWM : 205.45 (+1.26%)
XBI : 88.29 (+1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The SPDR SP Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the SP Biotechnology Select Industry Index.

See More

Key Turning Points

3rd Resistance Point 91.77
2nd Resistance Point 90.32
1st Resistance Point 89.30
Last Price 88.29
1st Support Level 86.83
2nd Support Level 85.38
3rd Support Level 84.36

See More

52-Week High 105.47
Fibonacci 61.8% 96.18
Fibonacci 50% 93.31
Fibonacci 38.2% 90.43
Last Price 88.29
52-Week Low 81.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar